We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Clotting Assay Predicts Patient Transfusion Needs

By LabMedica International staff writers
Posted on 30 May 2017
A new test that quantifies clotting ability can help identify trauma patients who are most in need of a massive blood transfusion, according to a new study.

The new test, developed by researchers at the University of Colorado School of Medicine, modifies thrombelastography (TEG)--a test that measures the viscoelastic properties of whole blood to determine the ability of blood to clot--by adding tissue plasminogen activator (tPA) to the blood sample. More...
As tPA saturates endogenous inhibitors, systemic hyperfibrinolysis occurs, which can help stratify the underlying degree of shock and identify early coagulation changes in order to predict progression to massive transfusion.

To test this hypothesis, the researchers analyzed blood samples from 324 trauma patients, of which 17% required a massive blood transfusion. Trauma activations were analyzed using rapid TEG and the modified TEG-tPA test. Clinical scores, which included shock index, assessment of blood consumption, and trauma-associated severe hemorrhage were then compared with TEG measurements to predict the need for massive transfusion, using areas under the receiver operating characteristic curves.

The results showed that rapid TEG and tPA-TEG parameters were significantly different in all massive transfusion patients compared to non-massive transfusion patients. Low-dose tPA lysis at 30 minutes had the largest the area under the receiver operating characteristic curve for prediction of massive transfusion, similar to the international normalized ratio (INR) of prothrombin time. When the tPA-TEG assay was used together with INR, it improved identification of patients in need of transfusion by 40%, and identified 97% of patients who did not, thereby preventing unnecessary transfusions. The study was published on May 15, 2017, in JACS.

“The tPA-TEG identifies trauma patients who require massive transfusion efficiently in a single assay that can be completed in a shorter time than other scoring systems, which has improved performance when combined with international normalized ratio,” concluded lead author Hunter B. Moore, MD, of the department of surgery. “This new method is consistent with our understanding of the molecular events responsible for trauma-induced coagulopathy.”

TEG is performed by gently rotating a blood sample through approximately 5º six times a minute in order to imitate sluggish venous flow and to activate coagulation. The speed at which the sample coagulates on a thin wire probe depends on the activity of the plasma coagulation system, platelet function, fibrinolysis, and other factors. The patterns of changes in strength and elasticity in the clot provide information about how well the blood can perform hemostasis, and how well or poorly different factors are contributing to clot formation.


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.